Financials data is unavailable for this security.
View more
Year on year Sartorius Stedim Biotech SA grew revenues 6.74% from 2.78bn to 2.97bn while net income improved 51.68% from 175.10m to 265.60m.
| Gross margin | 45.33% |
|---|---|
| Net profit margin | 8.97% |
| Operating margin | 17.72% |
| Return on assets | 3.28% |
|---|---|
| Return on equity | 6.58% |
| Return on investment | 3.85% |
More ▼
Cash flow in EURView more
In 2025, cash reserves at Sartorius Stedim Biotech SA fell by 252.80m. However, the company earned 692.20m from its operations for a Cash Flow Margin of 23.33%. In addition the company used 397.70m on investing activities and also paid 542.80m in financing cash flows.
| Cash flow per share | 5.98 |
|---|---|
| Price/Cash flow per share | 28.44 |
| Book value per share | 42.04 |
|---|---|
| Tangible book value per share | -3.39 |
More ▼
Balance sheet in EURView more
| Current ratio | 1.02 |
|---|---|
| Quick ratio | 0.5313 |
| Total debt/total equity | 0.6354 |
|---|---|
| Total debt/total capital | 0.3865 |
More ▼
Growth rates in EUR
SmartText is unavailable
| Div yield(5 year avg) | 0.34% |
|---|---|
| Div growth rate (5 year) | 0.29% |
| Payout ratio (TTM) | 25.26% |
| EPS growth(5 years) | -5.62 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 50.37 |
More ▼
